You just read:

New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients

News provided by

Takeda Pharmaceutical Company Limited

Oct 16, 2017, 08:00 ET